Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
ARLINGTON, Va., April 12, 2016 -- FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank serving the middle market, announced that Chris Meekins recently joined its equity research group and has initiated coverage on healthcare policy. Mr. Meekins is based in the Company’s Arlington, VA headquarters.
“Chris’s addition to our team brings a meaningful and unique policy perspective to our healthcare research that our clients want,” said FBR’s Director of Research and Senior Managing Director, David Hilal. “We have a great tradition of weaving together actionable investment ideas that are at the intersection of government policy and fundamental analysis. For the healthcare industry in particular, this differentiated approach provides our clients with tremendous value.”
Mr. Meekins came to FBR having spent four years as a senior health policy advisor and Chief of Staff for Congressman Andy Harris, M.D. During his tenure there, he helped pass reforms to the National Institutes of Health, increase funding for bio-defense, expand access to organs for transplantation, improve Medicare payments for physicians and increase transparency at the Food and Drug Administration. Before serving on the Hill, he worked in government affairs for the American Society of Anesthesiologists. Mr. Meekins holds a Bachelors of Arts from Gardner-Webb University.
FBR & Co. (Nasdaq:FBRC) provides investment banking, merger and acquisition advisory, institutional brokerage, and research services through its subsidiaries FBR Capital Markets & Co. and MLV & Co. FBR focuses capital and financial expertise on the following industry sectors: consumer; energy & natural resources; financial institutions; healthcare; industrials; insurance; real estate; and technology, media & telecom. FBR is headquartered in the Washington, D.C. metropolitan area with offices throughout the United States. For more information, please visit www.fbr.com.
Contacts Media: Shannon Hawkins at 703.469.1190 or [email protected] Investors: Linda E. Eddy at 703.312.9715 or [email protected]
